Biomedica	Management Corporation
	Bright Minds at work on 3 unique technologies Hemostatics for high volume hemorrhage, Sepsis and Ischemia			ClotFoam and the Future of Laparoscopic Surgery Glyco 23: A Cost-effective Tretament for Sepsis
	Who we are			What we do
	Ours is a business of practical solutions to biotechnological challenges. Biomedica Management Corporation is a privately-held research and development small company headquartered at the SUNY Downstate Biotech Center in Brooklyn, NY, with biochemistry labs at the UMBC TechCenter in Baltimore, MD. The company was formed in 1999 under an innovative business model that explores and develops critical technologies in collaboration with academic scientists. Very early in its development, Biomedica recognized that critical, affordable and effective technologies-targeting prevalent diseases and conditions with the potential to lead in multimillion dollar markets-are the prescription for success.			The company is developing a pipeline of novel treatments in inflammation, sepsis, wound healing and tissue regeneration with civilian and military applications, which address serious unmet medical needs. Its leading technology, ClotFoam, is a hemostatic agent for use in non-compressible high-volume hemorrhage. This platform technology has important applications in trauma, laparoscopic surgery and wound healing. Second in the pipeline is a glycolipid derivative (Glyco 23) for the treatment of sepsis, followed by a small-molecule selectin blocker with anti-ischemic properties (Neutrolide), for application in ischemic conditions in transplantation, resuscitation, and vascular disease. We select therapeutic targets with strong preclinical or clinical validation in areas where we have the potential to generate either first-in-class therapies that are either not currently available, or that are highly differentiated from existing treatments. Our chemistry, surgical, clinical and biology teams and efforts are highly integrated, and are characterized by the rapid generation of relevant data for each therapeutic target we pursue. This process allows our scientists to better understand- in real time-the potency, selectivity and potential safety of the compounds. Indeed, having the ability to test biochemical improvements right away, our research and development process moves very fast. If we were to look two years into the future, we see over 60 percent of surgical procedures conducted with minimally-invasive laparoscopic techniques, using non-compressible hemostatic agents such as ClotFoam; and a substantial improvement in life saving procedures following accidents and other traumatic events, including casualties in the battlefield. Three years from now, we expect to prevent or control the development of sepsis without antibiotics, by drugs that are affordable and have no contraindications